Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03455764 · ClinicalTrials.gov registry record · Phase 1

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

A Phase 1 study of Melanoma, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT03455764: Completed Phase 1 study of Melanoma, sponsored by Dana-Farber Cancer Institute.

NCT03455764 is a Phase 1 study of Melanoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03455764, a Phase 1 study of Melanoma, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventions involved in this study are: * MCS110 * Dabrafenib * Trametinib

Primary Outcome

A DLT was defined as an adverse event that (a) was possibly, probably, or definitely related to the study medication regimen and (b) experienced during the first cycle of treatment, and (c) met any of the following criteria: ≥ Grade 3 non-hematological toxicity; grade 3 thrombocytopenia with clinically significant bleeding; grade 4 thrombocytopenia; ≥ grade 3 febrile neutropenia; grade 4 anemia; holding of any study medication due to toxicity for a period of greater than 8 consecutive days or tw

Conditions Studied

Melanoma

Interventions

  • DRUG Trametinib
  • DRUG Dabrafenib
  • DRUG MCS110

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2018-09-10
Est. Completion 2023-09-05
Phase Phase 1
Dana-Farber Cancer Institute

781 total trials

What the finished NCT03455764 record still lists

NCT03455764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Trametinib is the first listed.

NCT03455764 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03455764 about?

NCT03455764 is a clinical study titled "MCS110 With BRAF/MEK Inhibition in Patients With Melanoma". This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventions involved in this study are: * MCS110 * Dabrafenib * Trametinib

What is the current status of trial NCT03455764?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-09-10. Estimated completion is 2023-09-05.

What conditions does trial NCT03455764 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT03455764?

The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), MCS110 (DRUG).

Who is sponsoring clinical trial NCT03455764?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03455764 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03455764's enrollment target sits among peer trials

6 261st of 266 higher than 4 of 266 other Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03455764, the US trial registry maintained by the National Library of Medicine. NCT03455764 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.